Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

All Dual-Eligibles Will Be Enrolled In Medicare Part D By Start Date, McClellan Says

This article was originally published in The Pink Sheet Daily

Executive Summary

The agency will employ auto-enrollment for beneficiaries eligible for Medicare and Medicaid by Jan. 1, 2006 to avoid potential coverage gaps, CMS Administrator McClellan says. The Medicare Today coalition kicks-off national public education campaign on Medicare Rx.

You may also be interested in...



One-Time Scripts For Non-Formulary Drugs Could Aid Part D Transition – CMS

Medicare Part D plans should provide a temporary “first-fill” prescription for new beneficiaries taking non-formulary drugs, CMS says. A 30-day supply “may be reasonable” for most beneficiaries, but for patients in long-term care “a transition period of 90 to 180 days might be appropriate.”

One-Time Scripts For Non-Formulary Drugs Could Aid Part D Transition – CMS

Medicare Part D plans should provide a temporary “first-fill” prescription for new beneficiaries taking non-formulary drugs, CMS says. A 30-day supply “may be reasonable” for most beneficiaries, but for patients in long-term care “a transition period of 90 to 180 days might be appropriate.”

CMS Urging States To Provide Extended-Supply Scripts To "Dual-Eligibles"

Prescriptions for 60- or 90-day supplies given to dual-eligibles at the end of 2005 would still receive federal matching coverage for state Medicaid programs and could decrease the likelihood of beneficiary coverage gaps, CMS Deputy Administrator Norwalk says.

Topics

UsernamePublicRestriction

Register

ID1135947

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel